5–Year relative survival rate: Age 20–44, 76%. Age 45–54, 67%. Age 55–64, 45%. Procarbazine, lomustine and vincristine have been used since May 1975. For 46 years, new therapeutic options have been regularly tested as part of therapy studies to improve the treatment of<unk> .
Anaplastic oligodendroglioma
Anaplastic astrocytoma
Neurothekeoma
Oligodendroglioma
Giant-cell glioblastoma
Subependymal giant cell astrocytoma
Fibrillary astrocytoma
Pilocytic astrocytoma